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Abstract
Background This phase I, four-arm, open-label study
(NCT01347866) evaluated the PI3K/mTOR inhibitors
PF-04691502 (arms A, B) and gedatolisib (PF-05212384;
arms C, D) in combination with the MEK inhibitor PD-
0325901 (arm A, D) or irinotecan (arm B, C) in patients
with advanced solid tumors.
Objectives Primary endpoint was dose-limiting toxicity with
each combination. Secondary endpoints included safety, phar-
macokinetics and preliminary antitumor activity.
Patients and Methods Dose escalation followed a 3 + 3 de-
sign in arm C and a zone-based design in arm D.
Results The PF-04691502 combination arms were closed
prematurely due to low tolerability, and the maximum
tolerated doses (MTDs) were not determined for either
arm. The MTD for the combination of gedatolisib with
irinotecan 180 mg/m2 was estimated to be 110 mg weekly
and for the combination with PD-0325901 was not reached at
the highest dose evaluated (gedatolisib 154 mg weekly).
Plasma concentrations of gedatolisib were generally sim-
ilar across dose groups in arm C (with irinotecan) and arm
D (with PD-0325901). Frequent dose delays or dose re-
ductions were required for both combinations, potentially
preventing sustained therapeutic drug concentrations.
Gedatolisib plus irinotecan produced a response rate of
~5% and clinical benefit in 16% of patients with advanced
colorectal cancer (progression-free survival, 2.8 months).
Preliminary evidence of clinical activity was observed
with gedatolisib plus PD-0325901 in patients with ovar-
ian cancer (three partial responses, n = 5) or endome-
trial cancer (one partial response, n = 1) and KRAS
mutations.
Conclusions Further evaluations of gedatolisib are warranted
in patients with advanced solid malignancies.
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1 Introduction
The phosphatidylinositol 3-kinase (PI3K)/AKT/mamma-
lian target of rapamycin (mTOR) and the mitogen-
activated protein kinase (MAPK; RAS-RAF-MEK-
ERK) pathways are aberrantly activated in many cancer
cells [1, 2]. RAS mutations are found in up to 30–40%
of patients, whereas BRAF mutations occur in ~10–12%
and PI3K muta t i ons in 10–18% of pa t i en t s .
Interestingly, RAS and PI3K mutations frequently coex-
ist in the same tumor, but RAS and BRAF mutations
are mutually exclusive [3]. It is known that these path-
ways converge at multiple points, and preclinical data
suggest that blockade of these pathways may lead to
upregulation of the other pathway via crosstalk [4–7].
Therefore, dual pathway blockade may be advantageous
in inhibiting tumor growth, thus providing a rationale
for evaluating the safety, tolerability and efficacy of
combinations of PI3K and MEK inhibitors in patients
with tumors bearing genetic aberrations of these path-
ways [8–12].
PF-04691502 is a potent dual inhibitor of both PI3K and
mTOR (target of rapamycin complex [TORC] 1 and 2)
kinase activity intended for once-daily oral dosing
[13–15]. The maximum tolerated dose (MTD) for single-
agent PF-04691502 in patients with solid malignancies
was determined to be 8 mg once daily [14]. Gedatolisib
(PF-05212384) is a potent pan-class I isoform inhibitor of
PI3K and mTOR (TORC1 and TORC2) kinase activity
intended for once-weekly intravenous (IV) infusion
[15–19]. The MTD for single-agent gedatolisib was esti-
mated to be 154 mg once weekly in patients with advanced
solid tumors [19]. PD-0325901 is a potent, selective, non-
ATP-competitive, oral, small-molecule inhibitor of both
MEK isoforms, MEK1 and MEK2 [20, 21]. This agent
demonstrated antiproliferative and antitumor activity in
preclinical models of cancer. The MTD for single-agent
PD-0325901 was estimated to be 15 mg orally twice a
day (BID) [21].
Both gedatolisib and PF-04691502 inhibit PI3K and
mTOR signaling in cell-based assays, resulting in antiprolif-
erative activity in culture and antitumor activity in xenograft
models [13, 16]. Treatment with gedatolisib produced tumor
growth inhibition or regression in multiple tumor types, in-
cluding colon (HCT116), breast (MDA-MB-361, BT474) and
lung cancer (H1975) xenograft models [16]. Preclinical data
also support synergistic effects of PI3K inhibitors with
irinotecan (topoisomerase I inhibitor) or PD-0325901 in solid
tumors, as demonstrated with gedatolisib in experimental
models of colorectal cancer (CRC) [16].
Aims of this multi-arm, dose-escalation, phase I study were
to determine the MTD and/or recommended phase II dose for
combination of the PI3K/mTOR inhibitors PF-04691502 and
gedatolisib with irinotecan or the MEK inhibitor PD-0325901
and to assess their safety, pharmacokinetics (PK) and prelim-
inary antitumor activity in patients with advanced solid tu-
mors. By evaluating the two PI3K/mTOR inhibitors in paral-
lel, with irinotecan or the MEK inhibitor, we sought to deter-
mine the most well-tolerated combination with which to move
forward in the expansion phase.
2 Patients and Methods
2.1 Study Design
Study B1271002 was initially intended as a phase I, four-arm,
open-label, multicenter, dose-escalation study of PF-
04691502 in combination with PD-0325901 (arm A) or
irinotecan (arm B) and of gedatolisib in combination with
irinotecan (arm C) or PD-0325901 (arm D) in patients with
advanced solid tumors (Table 1). However, as a result of the
emerging safety and antitumor activity data, the second study
protocol amendment terminated enrollment to both PF-
04691502 arms. Arm A (PF-04691502 in combination with
PD-0325901) was closed due to the frequent dose interrup-
tions and dose reductions associated with treatment-related
adverse events (AEs). Arm B (PF-04691502 in combination
with irinotecan) was closed because of the more encouraging
antitumor activity and safety profile observed in arm C
(gedatolisib in combination with irinotecan). As a result of
the better tolerability profile and higher antitumor activity
seen in arm C compared with arm B, a further arm, D, was
included to evaluate the combination of gedatolisib with PD-
0325901. Following dose escalation in stage 1, an expansion
cohort (stage 2) was enrolled for arm C.
The primary objective of the study was to assess the safety
and tolerability and define the MTD for each combination
(primary endpoint: dose-limiting toxicity [DLT]). Secondary
Key Points
This study evaluated safety, pharmacokinetics, and 
preliminary antitumor activity of the PI3K/mTOR 
inhibitor gedatolisib plus irinotecan or the MEK inhibitor
PD-0325901. 
Gedatolisib combined with irinotecan had limited activity
in patients with advanced colorectal cancer.
Antitumor activity was observed with gedatolisib in 
combination with PD-0325901 in patients with ovarian 
or endometrial cancer and KRAS mutations.
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endpoints included evaluation of the safety profile of each
combination, characterization of single- and multiple-dose
PKs for gedatolisib, PD-0325901 and PD-0315209
(metabolite of PD-0325901) when administered in combina-
tion; assessment of the antitumor activity of the combinations;
and evaluation of pretreatment tumor samples (fresh or ar-
chived) for genetic alterations that might predict tumor
response.
The study was approved by the institutional review board
or independent ethics committee of each participating center
and followed the Declaration of Helsinki and International
Conference on Harmonization Good Clinical Practice guide-
lines. All subjects gave written informed consent. The study
was sponsored by Pfizer and registered at ClinicalTrials.gov
(NCT01347866).
2.2 Eligible Patients
Patients 18 years of age or older with a histologic or cytologic
diagnosis of advanced/metastatic solid tumor for which there
was no current clinically effective treatment were included in
the study. Patients had to have adequate bone marrow, renal,
liver and cardiac functions, and adequate glucose control (in-
cluding no previous diagnosis of diabetes mellitus and hemo-
globin A1C <7%). Only patients with Eastern Cooperative
Oncology Group performance status 0 or 1 were eligible.
Patients enrolled in stage 2 (expansion cohort) of arm C were
required to have metastatic CRC (regardless of KRAS muta-
tion status), which had progressed on irinotecan-based regi-
mens, or pancreatic ductal adenocarcinoma after progression
on first-line treatment for advanced disease. Patients enrolled
in stage 1 (dose escalation) of arm D were required to have
tumors with KRAS or BRAF mutation (archived or fresh
biopsy).
Patients with known active brain metastases, clinically de-
compensated cardiovascular disease, impaired pulmonary
function, or surgery within 4 weeks prior to the start of study
treatment were not eligible. Additionally, chemotherapy, ra-
diotherapy and biologic or investigational anticancer therapy
within 4 weeks prior to the start of study treatment were not
allowed. Use of or anticipated need for cytochrome P450 3A4
inhibitors/inducers or drugs known to be UGT1A9 substrates,
and concurrent administration of herbal preparations were also
not permitted.
2.3 Study Treatments
Treatment schedules for arms A and B are summarized in
Supplementary Information. In arm C, gedatolisib was dosed
as an IV infusion weekly on days 2, 9, 16 and 23 of each 28-
day cycle; irinotecan 180mg/m2was administered IVondays 1
and 15 of each 28-day cycle. In arm D, gedatolisib was
dosed as an IV infusion weekly on days −14 (during the PKTa
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lead-in portion of study), and on days 1, 8, 15 and 22 of each
28-day cycle. PD-0325901 was administered orally BID from
day −7 to day −1 (during the PK lead-in portion of the study)
and on days 1–21 of each 28-day cycle. Dose levels and pa-
tient groups for arms A to D are listed in Table 1.
In arm C, the starting dose was gedatolisib 95 mg, which
was escalated using the classical 3 + 3 design. Initially, up to
three patients were to be treated at each dose level (DL). If a
DLTwas observed in one of the three initially treated patients,
three additional patients were to be enrolled and treated at the
sameDL. A zone-based designwas used for dose escalation in
arm D, consisting of a modified 3 + 3 design that allowed
opening more than one DL at the same time once DL0 had
been completed. Dose escalation continued until an MTD (or
two MTDs) was defined or the maximum allowable dose was
reached. The starting dose levels for arm D (DL0) were
gedatolisib 110 mg and PD-0325901 2 mg BID (Table 1).
Once it had been established that the DL0 (110 mg + 2 mg)
was safe (no DLT in three patients or ≤1 DLT in six patients),
DL1 (110 mg + 4 mg) and DLA (130 mg + 2 mg) could be
opened.
2.4 Dose-Limiting Toxicity and Maximum Tolerated Dose
A DLT was defined as any of the following AEs (classified
according to the Common Terminology Criteria for Adverse
Events [CTCAE] version 4.0) that were attributable to the
combination study drug (i.e., deemed by the investigator to
be at least possibly related) and occurring in the first cycle
(28 days of treatment): (i) hematologic AEs: grade 4 neutro-
penia lasting >7 days, febrile neutropenia, grade ≥ 3 neutro-
penic infection, grade 3 thrombocytopenia with bleeding,
grade 4 thrombocytopenia; (ii) non-hematologic AEs:
grade ≥ 3 toxicities, except those that had not been optimally
treated (i.e., nausea, vomiting, diarrhea, hyperglycemia);
grade 3 corrected QT prolongation >500 msec persisting after
correction of any reversible causes (i.e., electrolyte abnormal-
ities or hypoxia); and persistent, intolerable toxicities (i.e.,
grade 2 mucosal inflammation, grade 2 neutropenia or grade 2
fatigue) resulting in failure to deliver at least 75% of doses
during the first cycle or in a delay >2 weeks in starting cycle 2.
The MTD estimate was the highest dose associated with the
occurrence of DLTs in <33% of patients in the first treatment
cycle, with the next higher dose having at least 2 of 3 to 6
patients experiencing DLTs.
2.5 Safety and Antitumor Activity Assessments
Safety evaluations included clinical monitoring, vital
signs, physical examination, 12-lead electrocardiogram,
cardiac function, collection of AEs and safety laboratory
test results. The AEs were graded according to CTCAE
v4.0 and coded using Medical Dictionary for Regulatory
Activities v18.1.
Antitumor activity was evaluated through radiologic tumor
assessments performed at baseline, every 8 weeks during
treatment (cycle 3 and beyond), whenever disease progression
was suspected (e.g., symptomatic deterioration) and at the
time of withdrawal from the study (if not done in the previous 6
weeks) or at the end of treatment. Responses were deter-
mined using Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1.
2.6 Pharmacokinetics and Genetic Markers
Blood samples were collected for PK analysis of PF-
04691502, gedatolisib, PD-0325901 and PD-0315209 (a
metabolite of PD-0325901) at predefined time points and
were assayed using validated analytical methods. The lower
limit of quantification (LLOQ) was 0.25 ng/mL for PF-
04691502, 1 ng/mL for PD-0325901 and 2 ng/mL for
gedatolisib. Samples below the LLOQ were set to zero for
analysis.
Patient samples (formalin-fixed paraffin-embedded tumor
tissues) were analyzed for genetic markers potentially corre-
lated to drug sensitivity, including phosphatase and tensin ho-
molog (PTEN) expression, KRAS/BRAF mutation status and
PIK3CA mutation. PTEN protein expression was assessed by
immunohistochemistry staining and reported as manual pa-
thologist scores (0, 1+, 2+ or 3+). KRAS and BRAF gene
mutation analyses were performed using the Qiagen KRAS
RGQ PCR assay (Qiagen, Manchester, UK). PIK3CA gene
mutation analysis was performed using a Roche Cobas
PIK3CA assay (Roche Molecular Diagnostics, Pleasanton,
CA, USA).
2.7 Statistical Analysis
Descriptive statistics were used throughout the study. The ob-
jective response rate (ORR) was summarized with an exact
two-sided 95% confidence interval (CI) calculated using the
Clopper–Pearson method. Progression-free survival (PFS),
defined as the time from first dose of study treatment to first
documentation of progression or death due to any cause, was
analyzed by descriptive statistics and the Kaplan–Meier meth-
od. The PK parameters were calculated for each patient using
non-compartmental analysis of concentration-time data.
3 Results
Seven and 14 patients were screened and received study treat-
ment in arm A (three dose-escalation groups) and arm B (two
dose-escalation groups), respectively (Table 1). A total of 45
patients were screened and 44 received study treatment in arm
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C: 13 patients in three dose-escalation groups/stage 1 and 31
patients in the expansion cohort/stage 2. In arm D, 39 patients
were screened and 37 received study treatment (eight dose-
escalation groups/stage 1). Patient demographic characteris-
tics and primary tumor diagnosis are summarized in Table 2.
The majority of patients had a primary diagnosis of advanced
CRC: 71%, 57%, 93% and 57% in arms A, B, C and D,
respectively. All 31 patients in the expansion cohort of arm
C (C2, stage 2) had advanced CRC. Five (14%) patients each
in the dose-escalation groups of arm D had advanced ovarian
and lung cancer. Approximately 57% of the patients in arms A
and B, and 68% of patients in arms C and D had received three
or more prior systemic anticancer treatment regimens. All pa-
tients have been discontinued from the study.
3.1 Safety
In arm A (PF-04691502 in combination with PD-0325901),
DLTs were reported in three of the seven DLT-evaluable pa-
tients. In group A1, one patient experienced grade 3 diarrhea,
grade 3 nausea and grade 3 vomiting not improved by symp-
tomatic treatment; one patient developed grade 4 mucosal
Table 2 Patient demographic
and baseline characteristics Arm A:
PF-
04691502 + PD-
0325901
Arm B:
PF-
04691502 + irinotecan
Arm C:
Gedatolisib +
irinotecan
Arm D:
Gedatolisib +
PD-0325901
n 7 14 44 37
Gender, n (%)
Male 4 (57.1) 7 (50) 25 (56.8) 22 (59.5)
Female 3 (42.9) 7 (50) 19 (43.2) 15 (40.5)
Age, years
Mean (range) 56.7 (49–73) 56.4 (37–81) 58.5 (33–78) 58.3 (33–75)
≥ 65, n (%) 1 (14.3) 4 (28.6) 15 (34.1) 14 (37.8)
Race, n (%)
White 7 (100) 14 (100) 34 (77.3) 33 (89.2)
Black 0 0 4 (9.1) 0
Asian 0 0 5 (11.4) 4 (10.8)
Other 0 0 1 (2.3) 0
Primary tumor
diagnosis, n (%)
Colorectal cancer 5 (71.4) 8 (57.1) 41 (93.2) 21 (56.8)
Lung cancer 0 0 1 (2.3) 5 (13.5)
Ovarian cancer 0 2 (14.3) 0 5 (13.5)
Pancreatic cancer 0 0 2 (4.5) 0
Breast cancer 1 (14.3) 1 (7.1) 0 0
Gastrointestinal
stromal tumor
1 (14.3) 0 0 0
Gastric cancer 0 1 (7.1) 0 1 (2.7)
Cholangiocarcinoma 0 1 (7.1) 0 1 (2.7)
Esophageal
carcinoma
0 1 (7.1) 0 0
Endometrial cancer 0 0 0 1 (2.7)
Liposarcoma 0 0 0 1 (2.7)
Cancer of the
appendix
0 0 0 1 (2.7)
Prostate cancer 0 0 0 1 (2.7)
No. of prior systemic
anticancer treatment(s), n (%)
1 0 2 (14.3) 6 (13.6) 2 (5.4)
2 3 (42.9) 4 (28.6) 8 (18.2) 10 (27.0)
3 2 (28.6) 3 (21.4) 11 (25.0) 10 (27.0)
> 3 2 (28.6) 5 (35.7) 19 (43.2) 15 (40.5)
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inflammation. In group A4, one patient experienced grade 3
increased blood alkaline phosphatase (Table 1 and
Supplementary Table S1). In arm A, five (71.4%) patients
experienced grade 3–4 all-causality AEs and five (71.4%)
pa t i en t s had g r ade 3–4 t r ea tmen t - r e l a t ed AEs
(Supplementary Tables S2 and S3).
In arm B (PF-04691502 in combination with irinotecan),
DLTs were reported in three of the 12 DLT-evaluable patients.
In group B1, one patient experienced grade 2 neutrope-
nia; in B2, one patient reported grade 2 fatigue and one
patient developed grade 3 febrile neutropenia (Table 1
and Supplementary Table S1; persistent AEs resulting in
failure to deliver at least 75% of doses during the first
cycle or in a delay >2 weeks in starting cycle 2 were
considered DLTs). Among all patients in arm B
(n = 14), seven (50%) patients experienced grade 3–4
all-causality AEs and four (28.6%) patients developed
grade 3–4 treatment-related AEs (Supplementary
Tables S2 and S4).
Both arms A and B of this study were closed prematurely
because of safety concerns and greater antitumor activity seen
in arms C and D. The MTDs for the combinations of PF-
04691502 with PD-0325901 or irinotecan were not estimated.
In arm C (gedatolisib in combination with irinotecan), all
13 patients in the dose-escalation stage were evaluable for
DLT. DLTs were reported in two patients treated at the
gedatolisib 130-mg dose level (group C3): one patient devel-
oped grade 4 febrile neutropenia and one patient experienced
grade 3 fatigue (Table 1 and Supplementary Table S1). The
MTD for gedatolisib in combination with irinotecan 180 mg/
m2 was estimated to be 110 mg weekly.
Among all patients in arm C (n = 44), 17 (38.6%) patients
experienced grade 3–4 all-causality AEs. Eleven (25.0%) pa-
tients developed grade 3–4 treatment-related AEs, including
grade 4 neutropenia (n = 3) and grade 4 febrile neutropenia
(n = 1). Treatment-related grade 3 AEs experienced by two or
more patients were neutropenia (n = 4) and asthenia (n = 2).
The most common treatment-related AEs were nausea
(61.4%), diarrhea (52.3%), vomiting (40.9%), mucosal
inflammation/stomatitis (34.1%), decreased appetite (31.8%)
and fatigue (29.5%), mostly of grade 1 or 2 (Table 3). Four
(9.1%) patients had all-causality AEs reported as the primary
reason for permanent ly discont inuing trea tment
(Supplementary Table S2). Ten (22.7%) patients temporarily
discontinued gedatolisib due to all-causality AEs; three
(6.8%) of these discontinuations were due to treatment-
related AEs. Eight (18.2%) patients temporarily discontinued
irinotecan due to all-causality AEs; two (4.5%) of these dis-
continuations were due to treatment-related AEs. Irinotecan
doses were reduced in 10 (22.7%) patients due to treatment-
related AEs.
In arm D (gedatolisib in combination with PD-0325901),
DLTs were reported in three of the 35 DLT-evaluable patients.
One patient (group D0) experienced grade 2 mucosal inflam-
ma t i o n , on e p a t i e n t ( g r oup D1 ) h ad g r a d e 3
hypophosphatemia and one patient (group D1A) had grade 3
stomatitis (Table 1 and Supplementary Table S1). The MTD
for combination treatment in arm D was not reached at the
highest dose level of gedatolisib evaluated in this study
(gedatolisib 154 mg weekly/PD-0325901 4 mg BID).
In arm D, 19 (51.4%) patients experienced grade 3–4 all-
causality AEs; eight (21.6%) patients had treatment-related
grade 3–4 AEs, including grade 3 mucosal inflammation/
stomatitis (n = 3); increased alanine and aspartate aminotrans-
ferase levels, hypophosphatemia, macular rash and proteinuria
(n = 1 each); and grade 4 hyperglycemia (n = 1) (Table 4). The
most common treatment-related AEs in arm D were mucosal
inflammation/stomatitis (67.6%), acneiform dermatitis
(40.5%), nausea (35.1%), fatigue (29.7%) and rash (29.7%).
Six (16.2%) patients had all-causality AEs as the primary
reason for permanent ly discont inuing trea tment
(Supplementary Table S2). Eighteen (48.6%) patients tempo-
rarily discontinued gedatolisib due to all-causality AEs; 15
(40.5%) of these discontinuations were due to treatment-
related AEs. Seventeen (45.9%) patients temporarily
discontinued PD-0325901 due to all-causality AEs, of which
12 (32.4%) were due to treatment-related AEs. Grade 5 AEs
were reported only in arm D in three (8.1%) patients (cardiac
tamponade, hypercalcemia and abdominal pain in patients
with disease progression) and deemed not related to study
treatment (Supplementary Table S2).
3.2 Antitumor Activity
In arm C, two patients with CRC (C1 and C2/stage 2 groups),
treated with gedatolisib in combination with irinotecan,
achieved a partial response (PR; i.e., at least a 30% reduction
from nadir; Fig. 1a). Both responders had received irinotecan
therapy for advanced disease prior to study entry. These two
patients remained on treatment for 189 and 359 days from first
dose, respectively. The ORR was 4.7% (95% CI: 0.6–15.8%).
Clinical benefit (defined as complete response [CR], PR or
stable disease ≥184 days) was seen in seven (16.3% [95%
CI: 6.8–30.7%]) patients. The median PFS, calculated only
for patients in the expansion cohort/stage 2 of arm C, was
2.8 (95% CI: 1.7–3.7) months.
In arm D, three patients with ovarian cancer (D0A, D1 and
D1A groups) and one patient with endometrial cancer (D1
group) treated with gedatolisib in combination with PD-
0325901 achieved a PR (Figure 1b), for an ORR of 11.1%
(95% CI: 3.1–26.1%). These four patients remained on treat-
ment for 153, 259, 244 and 376 days, respectively, from first
dose. Clinical benefit was seen in five (13.9% [95% CI: 4.7–
29.5%]) patients.
Among responders in both arms C and D, five of the five
PTEN-evaluable patients were PTEN+, four of the fiveKRAS-
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evaluable patients had a detectable KRAS mutation in either
ovarian (G12A, G12 V and G13D) or endometrial cancer
(G12D) and one of the two phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic subunit alpha gene
(PIK3CA)-evaluable patients had a detectable mutation
(H1047R) in endometrial cancer. No BRAF mutations were
detected in the three BRAF-evaluable responders
(Supplementary Table S5).
3.3 Pharmacokinetics
Gedatolisib PK profiles are presented for arm C (in combina-
tion with irinotecan) and arm D (in combination with PD-
0325901). Median plasma concentration–time profiles of
gedatolisib in arms C and D are shown in Fig. 2. Plasma
gedatolisib PK parameters during once-weekly administration
are summarized in Supplementary Table S6 for armC (cycle 1,
days 2 and 16) and Supplementary Table S7 for arm D
(lead-in and cycle 1, day 15). The range of gedatolisib doses
administered was less than twofold, ranging from 95 to
130 mg in arm C and from 110 to 154 mg in arm D. Plasma
gedatolisib PK parameters were generally similar across the
different treatment groups in both arms C and D, with a trend
toward higher exposure (maximum plasma concentration and
area under the plasma concentration–time profile) at higher
doses, but with considerable overlap between the dose levels.
Mean terminal half-life ranged from 24 to 41 h.
The PK parameters for PD-0325901 in arm D are summa-
rized in Supplementary Table S8 for lead-in (day −1) and
cycle 1, day 1 following oral doses of 2 mg to 6 mg BID
starting on day −7 of the lead-in phase. The PK parameters
were similar for both time points. Plasma PD-0325901
Table 3 Treatment-related
adverse events reported in >15%
of patients in arm C (n = 44)
Adverse event, n (%) Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Total
Any adverse event 13 (29.5) 19 (43.2) 7 (15.9)a 4 (9.1)b 0 43 (97.7)
Nausea 19 (43.2) 8 (18.2) 0 0 0 27 (61.4)
Diarrhea 15 (34.1) 7 (15.9) 1 (2.3) 0 0 23 (52.3)
Vomiting 13 (29.5) 5 (11.4) 0 0 0 18 (40.9)
Mucosal inflammation/stomatitis 14 (31.8) 1 (2.3) 0 0 0 15 (34.1)c
Decreased appetite 10 (22.7) 4 (9.1) 0 0 0 14 (31.8)
Fatigue 7 (15.9) 5 (11.4) 1 (2.3) 0 0 13 (29.5)
Alopecia 8 (18.2) 2 (4.5) 0 0 0 10 (22.7)
Neutropenia 0 2 (4.5) 4 (9.1) 3 (6.8) 0 9 (20.5)
Asthenia 3 (6.8) 4 (9.1) 2 (4.5) 0 0 9 (20.5)
Abdominal pain 5 (11.4) 2 (4.5) 0 0 0 7 (15.9)
a One patient each had grade 3 hyperglycemia, pyrexia, bacteremia (Escherichia), leucopenia and anemia
bOne patient had grade 4 febrile neutropenia
c One patient had both mucosal inflammation and stomatitis which were reported as separate, treatment-related
AEs. This patient is counted twice in the category of mucosal inflammation and stomatitis
Table 4 Treatment-related
adverse events reported in >15%
of patients in arm D (n = 37)
Adverse event, n (%) Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Total
Any adverse event 8 (21.6) 20 (54.1) 7 (18.9)a 1 (2.7)b 0 36 (97.3)
Mucosal inflammation/stomatitis 14 (37.8) 8 (21.6) 3 (8.1) 0 0 25 (67.6)
Acneiform dermatitis 11 (29.7) 4 (10.8) 0 0 0 15 (40.5)
Nausea 10 (27.0) 3 (8.1) 0 0 0 13 (35.1)
Fatigue 7 (18.9) 4 (10.8) 0 0 0 11 (29.7)
Rash 6 (16.2) 5 (13.5) 0 0 0 11 (29.7)
Diarrhea 7 (18.9) 3 (8.1) 0 0 0 10 (27.0)
Maculopapular rash 6 (16.2) 3 (8.1) 0 0 0 9 (24.3)
Dry mouth 8 (21.6) 0 0 0 0 8 (21.6)
Vomiting 5 (13.5) 3 (8.1) 0 0 0 8 (21.6)
Increased aspartate aminotransferase 3 (8.1) 2 (5.4) 1 (2.7) 0 0 6 (16.2)
Asthenia 2 (5.4) 4 (10.8) 0 0 0 6 (16.2)
a One patient each had grade 3 increased alanine aminotransferase, hypophosphatemia, macular rash and protein-
uria. b One patient developed grade 4 hyperglycemia
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exposure (maximum concentration and area under the plasma
concentration–time profile from time zero to 8 h post dose)
appeared to increase proportionally with the twofold increase
in dose from 2 mg to 4 mg BID; however, exposure for 6 mg
BID was similar to that for 4 mg BID.
4 Discussion
In this multi-arm,multi-dose, phase I study we evaluated com-
binations of the PI3K/mTOR inhibitors PF-04691502 and
gedatolisib with either irinotecan or the MEK inhibitor PD-
0325901 in the treatment of patients with advanced solid ma-
lignancies. The PF-04691502 arms A and B were closed prior
to arms C and D due to the low tolerability profiles of the
combinations investigated and the more encouraging antitu-
mor activity observed in arms C and D with gedatolisib in
combination with irinotecan or PD-0325901.
Arm C, unlike the other arms in this study, consisted of a
fairly homogenous group of patients with advanced CRC. As
one of the requirements of this arm was to enroll patients
progressing on irinotecan-based therapies, the goal was to
reverse the chemoresistance associated with irinotecan by
adding a PI3K inhibitor. Similar strategies were successful in
the early development of cetuximab in this indication [22]. In
our study, the combination of gedatolisib with irinotecan in-
duced a response rate of ~5% and clinical benefit in 16% of
patients, with a PFS of 2.8 months, which is consistent with
previous reports in patients with refractory CRC [23, 24].
Furthermore, similar to other studies with PI3K inhibitors in
metastatic CRC, there was no clear correlation between clin-
ical benefit and the presence of activating PI3K mutations
[25]. In our study, plasma concentrations of gedatolisib were
generally similar across all dose groups in arm C (with
irinotecan) and arm D (with PD-0325901). However, there
was a trend toward higher exposure with higher doses across
the dose range of 95mg to 154mg once weekly. This suggests
A
B
Fig. 1 Waterfall plot of best
response for patients in (a) arm C
and (b) arm D
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the combinations did reach active concentrations that affected
target modulation in both study arms. However, frequent dose
delays (for both gedatolisib and irinotecan) and dose reduc-
tions (for irinotecan) were required in arm C to manage the
toxicities emerging during combination treatment. The most
common AEs related to treatment with dual PI3K/mTOR in-
hibitors appeared to be primarily gastrointestinal in nature
(e.g. diarrhea, nausea and vomiting), similar to the findings
reported for dactolisib (BEZ235) in combination with evero-
limus in patients with advanced tumors [26].
In arm D, all patients enrolled had mutations in either
KRAS or BRAF by trial design, suggesting potential clinical
benefit in the combinations evaluated. Plasma PD-0325901
PK was similar across all treatment groups and plasma PD-
0325901 exposures appeared to increase proportionally with
dose from 2 mg to 4 mg BID, whereas exposure for 6 mg BID
was similar to that of 4 mg BID. In this arm, we observed
responses and clinical benefit with gedatolisib in combination
with PD-0325901 in patients with KRASmutations, including
patients with low-grade ovarian or endometrial cancer. Three
of the five (60%) patients with ovarian cancer achieved a PR
and two (40%) had stable disease, indicating clinical activity
in this setting. The only patient with endometrial cancer en-
rolled in this study had a PR and a detectable PIK3CA
H1047R mutation. This finding is consistent with prior
phase II results, indicating clinical benefit from treatment with
single-agent gedatolisib in 40% of patients (n = 38) with re-
current endometrial cancer (16% ORR, one CR) [15].
Interestingly, other preclinical and clinical studies have previ-
ously suggested a potential association of the PIK3CA
A
B
Fig. 2 Median plasma
concentration–time profile of
gedatolisib in (a) arm C (cycle
1/day 16) and (b) arm D (cycle
1/day 15)
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H1047R mutation with response to treatment with
PI3K/AKT/mTOR inhibitors [25, 27].
Unfortunately, overall treatment in arm D was complicated
by grade > 2 AEs, which affected continuous dosing. Frequent
dose delays were required for both combination drugs, which
may have prevented therapeutic drug concentrations from be-
ing sustained over time. However, the combination of these
two targeted therapies clearly has activity in KRAS-mutated
ovarian cancer. Similarly, other trials evaluating the safety and
efficacy of different combinations of PI3K and MAPK path-
way inhibitors have shown antitumor activity, but the majority
have been consistently associated with higher than expected
toxicities [12, 28, 29]. Our trial was somewhat unique in that
its main focus was in combination with chemotherapy, a dif-
ferent strategy from most other PI3K inhibitors in develop-
ment. While no further development is currently in progress
for PF-04691502 or gedatolisib in combination with
irinotecan or PD-0325901, there are additional trials with
gedatolisib in combination with cisplatin in triple-negative
breast cancer to exploit the preclinical synergy seen when
gedatolisib is combined with cytotoxic therapies.
Further investigations may help address the challenges en-
countered in the clinical development of PI3K inhibitors, with
the identification of tolerable and effective schedules and
combinations of PI3K inhibitors with other agents or chemo-
therapies. In addition, they may provide new insights into the
apparent lack of consistent correlations of PI3K/mTOR or
pan-PI3K inhibitors effects with pathway aberrations [25,
30–33]. A new phase I study (NCT02684032) is currently in
progress to evaluate gedatolisib in combination with the
cyclin-dependent kinase 4/6 inhibitor palbociclib and either
letrozole or fulvestrant in patients with estrogen receptor-pos-
itive/human epidermal growth factor receptor 2-negative ad-
vanced breast cancer.
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